{"id":112853,"date":"2009-12-02T17:04:00","date_gmt":"2009-12-02T22:04:00","guid":{"rendered":"tag:typepad.com,2003:post-6a00d8341c89dd53ef0120a66eb16b970b"},"modified":"2009-12-02T17:10:42","modified_gmt":"2009-12-02T22:10:42","slug":"november-2009-osteonecrosis-of-the-jaw-onj-and-fosamax-four-recent-medical-journal-articles","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/112853","title":{"rendered":"November 2009: Osteonecrosis Of The Jaw (ONJ) And Fosamax: Four Recent Medical Journal Articles"},"content":{"rendered":"<div xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<p><strong><span style=\"FONT-SIZE: 14px; FONT-FAMILY: \"><span style=\"FONT-SIZE: 15px; FONT-FAMILY: \"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: \">This List Of Abstracts Provides Various Perspectives About\u00a0ONJ,\u00a0A<\/span><\/span><\/span><\/strong><strong><span style=\"FONT-SIZE: 14px; FONT-FAMILY: \"><span style=\"FONT-SIZE: 15px; FONT-FAMILY: \"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: \">\u00a0Jaw Bone\u00a0Side Effect\u00a0Caused By Bisphosphonates<\/span><\/span><\/span><\/strong><\/p>\n<p><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><font size=\"2\"><strong>(Posted by Tom Lamb at <a href=\"http:\/\/www.drug-injury.com\/\" ><span style=\"COLOR: #003366\"><font size=\"2\"><strong>DrugInjuryWatch.com<\/strong><\/font><\/span><\/a><font size=\"2\"><strong>)<\/strong><\/font><\/strong><\/font><\/span><\/span><\/span><\/span><\/p>\n<p>In this brief article we provide a quick round-up of medical journal articles published in November 2009 that address different aspects of how osteonecrosis of the jaw (ONJ) can develop in patients using bisphosphonates, a class of drugs which includes Fosamax.<\/p>\n<p><a href=\"http:\/\/highwire.stanford.edu\/cgi\/medline\/pmid;19884275\" >Osteonecrosis of the Jaw Correlated to Bisphosphonate Therapy in Non-oncologic Patients: Clinicopathological Features of 24 Patients.<\/a><br \/><em>The Journal of Rheumatology<\/em>, November 2, 2009<\/p>\n<p><a href=\"http:\/\/theoncologist.alphamedpress.org\/cgi\/content\/abstract\/14\/11\/1154\" >Bisphosphonates and Time to Osteonecrosis Development<\/a><br \/><em>The Oncologist<\/em>, November 8, 2009<\/p>\n<p><a href=\"http:\/\/informahealthcare.com\/doi\/abs\/10.3109\/00365590903295193\" >Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw<\/a><br \/><em>Scandinavian Journal of Urology and Nephrology<\/em>, November 10, 2009<\/p>\n<p><a href=\"http:\/\/radiographics.rsna.org\/content\/29\/7\/1971.abstract\" >Bisphosphonate-related Osteonecrosis of the Jaw: A Pictorial Review<\/a><br \/><em>RadioGraphics<\/em>, November 2009<\/p>\n<p>We will continue to watch for new medical journal articles about how and when Fosamax might cause osteonecrosis of the jaw (ONJ).<\/p>\n<p>If you are aware of a recent article about Fosamax or one of the other bisphosphonates being associated with ONJ &#8212; or osteomyelitis involving the jaw bone &#8212; now or going forward, please let us know about it by submitting a Comment, below.<\/p>\n<p>______________________________________________________________________________<\/p>\n<p><a href=\"http:\/\/www.druginjurylaw.com\/\" ><strong><span style=\"FONT-SIZE: 14px; FONT-FAMILY: \"><font color=\"#810081\">DrugInjuryLaw.com<\/font><\/span><\/strong><\/a>: <span style=\"COLOR: #ff0000; FONT-FAMILY: \"><span style=\"COLOR: #80c0ff; FONT-FAMILY: \"><span style=\"COLOR: #800000; FONT-FAMILY: \"><span style=\"COLOR: #302449; FONT-FAMILY: \"><strong>Legal Information And News About Prescription Drug Side Effects<\/strong><\/span><\/span><\/span><\/span><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F10%2Fdrug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fbyetta-exenatide-kidney-function-renal-failure-fda-dear-doctor-label-change-october-2009.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Faranesp-darbepoetin-alfa-associated-with-heightened-stroke-risk-amgen-treat-study-nejm-october.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fanemia-drugs-aranesp-procrit-blood-clots-study-esas-thromboembolism-dvt-pe-stroke.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fconsumers-unions-safe-patient-project-forum-webcast-to-err-is-human-to-delay-is-deadly.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fdrug-industry-document-archive-dida-ucsf-november-2009-additions.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fyaz-drsp-safety-inas-oc-study-venous-thrombosis-pulmonary-embolism-myocardial-infarction-cerebrovascular-accidents.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fmeridia-stroke-heart-attack-cardiac-death-fda-sibutramine-early-communication.html\" type=\"text\/javascript\"><\/script><\/div>\n<div class=\"feedflare\">\n<a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=eJm7VdeQWWA:Z5ajmvjTxkM:yIl2AUoC8zA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?d=yIl2AUoC8zA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=eJm7VdeQWWA:Z5ajmvjTxkM:F7zBnMyn0Lo\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?i=eJm7VdeQWWA:Z5ajmvjTxkM:F7zBnMyn0Lo\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=eJm7VdeQWWA:Z5ajmvjTxkM:V_sGLiPBpWU\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?i=eJm7VdeQWWA:Z5ajmvjTxkM:V_sGLiPBpWU\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=eJm7VdeQWWA:Z5ajmvjTxkM:l6gmwiTKsz0\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?d=l6gmwiTKsz0\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=eJm7VdeQWWA:Z5ajmvjTxkM:gIN9vFwOqvQ\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?i=eJm7VdeQWWA:Z5ajmvjTxkM:gIN9vFwOqvQ\" border=\"0\"><\/img><\/a>\n<\/div>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/drug-injury-watch\/~4\/eJm7VdeQWWA\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>This List Of Abstracts Provides Various Perspectives About\u00a0ONJ,\u00a0A\u00a0Jaw Bone\u00a0Side Effect\u00a0Caused By Bisphosphonates (Posted by Tom Lamb at DrugInjuryWatch.com) In this brief article we provide a quick round-up of medical journal articles published in November 2009 that address different aspects of how osteonecrosis of the jaw (ONJ) can develop in patients using bisphosphonates, a class of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-112853","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/112853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=112853"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/112853\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=112853"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=112853"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=112853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}